IM Cannabis (IMCC) Amortization of Deferred Charges (2020 - 2026)
IM Cannabis' (IMCC) quarterly Amortization of Deferred Charges came in at $62711.7 in Q1 2026, up 13.9% year-on-year from $55056.4 in Q1 2025, and up 6.55% quarter-over-quarter from $58857.4 in Q3 2025.
IM Cannabis (IMCC) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
IM Cannabis' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $62711.7 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 13.9% year-over-year to $62711.7 in Q1 2026; TTM through Mar 2026 was $228588.8, a 1.87% increase from a year earlier, with the FY2024 full-year figure at $256370.2, down 41.77% from the prior year.
- Amortization of Deferred Charges advanced to $62711.7 in Q1 2026 per IMCC's latest filing, from $58857.4 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $667473.9 in Q2 2022 and bottomed at $51963.3 in Q2 2025.
- The 5-year median for Amortization of Deferred Charges is $77351.6 (2023), against an average of $151342.4.
- Across the five-year window, Amortization of Deferred Charges surged 134.42% in 2022 and slumped 82.13% in 2023, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $324149.3 in 2022, then sank by 65.56% to $111649.4 in 2023, then plunged by 50.63% to $55120.4 in 2024, then rose by 6.78% to $58857.4 in 2025, then rose by 6.55% to $62711.7 in 2026.
- Per Business Quant, the three latest IMCC Amortization of Deferred Charges figures stand at $62711.7 (Q1 2026), $58857.4 (Q3 2025), and $51963.3 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,711.69 |
| Mar 31, 2026 | 62,711.69 |
| Sep 30, 2025 | 58,857.44 |
| Sep 30, 2025 | 58,857.44 |
| Jun 30, 2025 | 51,963.30 |
| Jun 30, 2025 | 51,963.30 |
| Mar 31, 2025 | 55,056.40 |
| Mar 31, 2025 | 55,056.40 |
| Dec 31, 2024 | 55,120.38 |
| Dec 31, 2024 | 55,120.38 |
| Sep 30, 2024 | 57,178.17 |
| Sep 30, 2024 | 57,178.17 |
| Jun 30, 2024 | 57,028.96 |
| Jun 30, 2024 | 57,028.96 |
| Mar 31, 2024 | 87,569.36 |
| Mar 31, 2024 | 87,569.36 |
| Dec 31, 2023 | 111,649.40 |
| Dec 31, 2023 | 111,649.40 |
| Sep 30, 2023 | 67,133.74 |
| Sep 30, 2023 | 67,133.74 |